Macrogenics Stock News

ROCKVILLE, MD, Feb. 03, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeu

Synaffix BV has entered into a technology agreement with MacroGenics Inc (NASDAQ: MGNX ). Under the licensing agreement, MacroGenics will access Synaffix''s clinical-stage GlycoConnect antibody conjugation technology, HydraSpace polar spacer technology, and select toxSYN linker-payloads. These will be combined with MacroGenics'' proprietary antibody and Full story available on Benzinga.com

ROCKVILLE, MD, Feb. 03, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeuti

Biotechnology company, Synaffix B.V. enters into a technology agreement with MacroGenics (MGNX) to gain access to Synaffix''s clinical stage GlycoConnect antibody conjugation…

Synaffix BV has entered into a technology agreement with MacroGenics Inc MGNX. Get the Inside Access Traders Are Using to Profit More and Win Bigger.

Macrogenics Inc (MGNX) shares closed today at 0.7% above its 52 week low of $12.81, giving the company a market cap of $790M. The stock is currently down 19.6% year-to-date, down 45.6% over the past 12 months, and down 34.1% over the past five years. This week, the Dow Jones Industrial Average fell 3.8%, and the S&P 500 fell 3.8%. Trading Activity Trading volume this week was 8.3% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.2. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 404.5% The company's stock price performance over the past 12 months lags the peer average by -746.7% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Macrogenics Inc (MGNX) shares closed today at 1.7% above its 52 week low of $14.54, giving the company a market cap of $906M. The stock is currently down 7.9% year-to-date, down 27.9% over the past 12 months, and down 26.9% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 13.8% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.2. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 379.9% The company's stock price performance over the past 12 months lags the peer average by -275.6% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Macrogenics Inc (MGNX) shares closed today at 1.7% above its 52 week low of $14.54, giving the company a market cap of $906M. The stock is currently down 7.9% year-to-date, down 29.8% over the past 12 months, and down 26.9% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 13.8% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.2. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.The stock closed at 6.2% lower than its 5-day moving average, 9.8% lower than its 20-day moving average, and 24.2% lower than its 90-day moving average. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 379.9% The company's stock price performance over the past 12 months lags the peer average by -281.2% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Macrogenics Inc (MGNX) shares closed 2.5% lower than its previous 52 week low, giving the company a market cap of $989M. The stock is currently up 0.7% year-to-date, down 27.2% over the past 12 months, and down 20.2% over the past five years. This week, the Dow Jones Industrial Average rose 1.1%, and the S&P 500 rose 0.1%. Trading Activity Trading volume this week was 27.5% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.1. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -161.6% The company's stock price performance over the past 12 months lags the peer average by -233.0% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Macrogenics Inc (MGNX) shares closed today at 1.2% above its 52 week low of $15.72, giving the company a market cap of $996M. The stock is currently down 28.9% year-to-date, down 33.6% over the past 12 months, and down 17.9% over the past five years. This week, the Dow Jones Industrial Average rose 2.6%, and the S&P 500 rose 3.0%. Trading Activity Trading volume this week was 46.8% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.1. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -230.3% The company's stock price performance over the past 12 months lags the peer average by -244.6% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

MacroGenics, Inc. (NASDAQ:MGNX) reached a new 52-week low on Tuesday . The stock traded as low as $15.74 and last traded at $16.23, with a volume of 396151 shares traded. The stock had previously closed at $16.20. MGNX has been the subject of several research analyst reports. Guggenheim initiated coverage on MacroGenics in a report []

Assenagon Asset Management S.A. cut its stake in shares of MacroGenics, Inc. (NASDAQ:MGNX) by 9.3% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 23,536 shares of the biopharmaceutical companys stock after selling 2,404 shares during the period. Assenagon Asset Management S.A.s holdings in MacroGenics were []

Shares of MacroGenics, Inc. (NASDAQ:MGNX) have received an average rating of Buy from the nine research firms that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating on the company. The average 1-year price []

Adagene (NASDAQ:ADAG) and MacroGenics (NASDAQ:MGNX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, earnings, institutional ownership, profitability, risk, dividends and analyst recommendations. Earnings and Valuation This table compares Adagene and MacroGenics gross revenue, earnings per share and valuation. Gross [] The post Adagene (NASDAQ:ADAG) & MacroGenics (NASDAQ:MGNX) Critical Review appeared first on ETF Daily News .

Adagene (NASDAQ:ADAG) and MacroGenics (NASDAQ:MGNX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, risk, valuation, dividends, profitability, analyst recommendations and institutional ownership. Profitability This table compares Adagene and MacroGenics net margins, return on equity and return on assets. Net []